Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis.

Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis.

Publication date: Oct 06, 2019

We investigated the ability of routine flow cytometry (FC) to detect nonhematologic neoplasms (non-HN) using antibody panels routinely used for the diagnosis of hematologic neoplasms.

FC analyses of 4,000 various diagnostic samples were retrospectively reviewed to identify cases in which an aberrant, viable CD45-negative, nonhematologic neoplastic population was detected by FC panels designed to evaluate hematologic neoplasms.

A total of 57 (1.4%) diverse non-HNs were identified, representing neuroendocrine tumors (33/57) and carcinomas (9/57), as well as other malignancies (15/57) such as sarcoma and melanoma. The majority of neoplasms were positive for at least one antibody, typically CD56 (43/51, 84.3%), followed by CD117 (15/34, 44.1%) and CD138 (6/33, 18.2%).

Our findings highlight the importance of carefully inspecting CD45-negative events to identify non-HNs by routine FC analysis. This can help expedite further downstream immunophenotypic analysis of specimens and triage samples for appropriate genetic and molecular studies.

Annunziata, J., Miller, M.L., Park, D.C., Vlad, G., Bhagat, G., and Alobeid, B. Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis. 24375. 2019 Am J Clin Pathol.

Concepts Keywords
Antibody Branches of biology
Carcinomas Medicine
CD117 Medical specialties
CD45 Flow cytometry
CD56 Anatomical pathology
Cytometry Neuroendocrine tumor
Flow Cytometry Neuroendocrinology
Genetic Pancreatic cancer
Hematologic Neoplasms Carcinoma
HNs Gate
Neuroendocrine Tumors


Type Source Name
disease DOID Carcinoma
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease DOID sarcoma
disease MESH sarcoma
disease MESH carcinomas
disease MESH neuroendocrine tumors
disease MESH hematologic neoplasms
disease MESH diagnosis
disease MESH Neoplasms

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *